Tharimmune (THAR)

• Market cap: $22.7M
• 1 day: -0.67%
• 5 days: 1.71%
• 1 month: 4.93%
• 3 months: 125.76%
• 6 months: 72.25%
• Year to date: 45.37%
• 1 year: -13.12%
• 5 years: -99.77%
• 10 years: -99.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Employees: 3